Toward a Molecular Pathologic Classification of Urothelial Carcinoma
Genome, Human
Kaplan-Meier Estimate
Immunohistochemistry
Pathology and Forensic Medicine
3. Good health
Gene Expression Regulation, Neoplastic
03 medical and health sciences
0302 clinical medicine
Urinary Bladder Neoplasms
Biomarkers, Tumor
Carcinoma, Squamous Cell
Humans
RNA, Messenger
Urothelium
Cell Proliferation
DOI:
10.1016/j.ajpath.2013.05.013
Publication Date:
2013-07-01T21:30:38Z
AUTHORS (13)
ABSTRACT
We recently defined molecular subtypes of urothelial carcinomas according to whole genome gene expression. Herein we describe molecular pathologic characterization of the subtypes using 20 genes and IHC of 237 tumors. In addition to differences in expression levels, the subtypes show important differences in stratification of protein expression. The selected genes included biological features central to bladder cancer biology, eg, cell cycle activity, cellular architecture, cell-cell interactions, and key receptor tyrosine kinases. We show that the urobasal (Uro) A subtype shares features with normal urothelium such as keratin 5 (KRT5), P-cadherin (P-Cad), and epidermal growth factor receptor (EGFR) expression confined to basal cells, and cell cycle activity (CCNB1) restricted to the tumor-stroma interface. In contrast, the squamous cell cancer-like (SCCL) subtype uniformly expresses KRT5, P-Cad, EGFR, KRT14, and cell cycle genes throughout the tumor parenchyma. The genomically unstable subtype shows proliferation throughout the tumor parenchyma and high ERBB2 and E-Cad expression but absence of KRT5, P-Cad, and EGFR expression. UroB tumors demonstrate features shared by both UroA and SCCL subtypes. A major transition in tumor progression seems to be loss of dependency of stromal interaction for proliferation. We present a simple IHC/histology-based classifier that is easy to implement as a standard pathologic evaluation to differentiate the three major subtypes: urobasal, genomically unstable, and SCCL. These three major subtypes exhibit important prognostic differences.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (21)
CITATIONS (152)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....